<From a strictly mathematical standpoint, the ballooning number of cancer-drug candidates is bearish in the aggregate for investors in biotech companies that are focused entirely in this area.>
Yes that makes sense. I also think it is worse for big pharma as they need the big blockbusters. With tumor typing the market for a drug gets split, making it harder to achieve or hold blockbuster status.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.